Guizhou Yibai Pharmaceutical Co., Ltd. (SHA:600594)

Market Cap	3.23B +14.4%
Revenue (ttm)	1.72B -18.2%
Net Income	-349.70M
EPS	-0.45
Shares Out	784.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,857,559
Average Volume	116,644,179
Open	4.090
Previous Close	4.120
Day's Range	4.040 - 4.150
52-Week Range	3.440 - 5.270
Beta	0.30
RSI	42.54
Earnings Date	Apr 23, 2026

About SHA:600594

Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatic bone, digestive system, pediatric, anti-infection, anti-inflammatory, analgesic, cancer, orthopedics, digestion, andrology, and urology. The company also engages in investme...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 5,261
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600594

Financial Performance

In 2025, SHA:600594's revenue was 1.86 billion, a decrease of -14.31% compared to the previous year's 2.17 billion. Losses were -329.56 million, 3.89% more than in 2024.